- Report
- October 2024
- 189 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- January 2025
- 150 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2025
- 187 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- April 2023
- 120 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- October 2023
- 190 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- November 2023
- 115 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- April 2024
- 132 Pages
Global
From €903EUR$950USD£759GBP
Peptide antibiotics are a type of antibiotic derived from peptides, which are short chains of amino acids. They are used to treat a variety of bacterial infections, including those caused by Gram-positive and Gram-negative bacteria. Peptide antibiotics are generally more effective than traditional antibiotics, as they are able to target specific bacterial cells and are less likely to cause resistance. They are also less likely to cause side effects, such as nausea and vomiting. Peptide antibiotics are typically administered intravenously or intramuscularly, and can be used in combination with other antibiotics.
The peptide antibiotics market is growing rapidly, driven by the increasing prevalence of antibiotic-resistant bacteria and the need for more effective treatments. The market is expected to continue to grow in the coming years, as more research is conducted into the development of new peptide antibiotics.
Some companies in the peptide antibiotics market include Merck, Pfizer, GlaxoSmithKline, Sanofi, and AstraZeneca. Show Less Read more